050-694 study - ZENworks 7 Desktop Management Administration Updated: 2024 | ||||||||
| killexams.com 050-694 exam brain dumps with practice test. | ||||||||
 |
||||||||
|
||||||||
|
Exam Code: 050-694 ZENworks 7 Desktop Management Administration study January 2024 by Killexams.com team | ||||||||
050-694 ZENworks 7 Desktop Management Administration Exam Detail: The exam with the code 050-694, also known as "ZENworks 7 Desktop Management Administration," is designed to assess the knowledge and skills of individuals in administering and managing Novell ZENworks 7 Desktop Management. Here is a detailed overview of the exam, including the number of questions and time, course outline, exam objectives, and exam syllabus. Number of Questions and Time: The exact number of questions in the 050-694 exam may vary, but it typically consists of approximately 60 to 70 multiple-choice and scenario-based questions. The duration of the exam is usually around 90 minutes. Course Outline: The 050-694 certification exam covers a wide range of syllabus related to the administration and management of Novell ZENworks 7 Desktop Management. The specific course outline may include the following components: 1. Introduction to ZENworks 7 Desktop Management: - Overview of ZENworks 7 features and architecture - Understanding the ZENworks 7 components and their functions - Installation and configuration of ZENworks 7 2. ZENworks 7 Configuration Management: - Managing user and device objects in ZENworks 7 - Distributing software packages and updates - Configuration policies and profiles - Inventory and asset management 3. ZENworks 7 Application Management: - Application packaging and deployment - Application associations and dependencies - Application rights and security - Application troubleshooting and maintenance 4. ZENworks 7 Imaging and Personality Migration: - Creating and deploying disk images - Personality migration and user settings - Imaging best practices and troubleshooting 5. ZENworks 7 Remote Management: - Remote control and remote diagnostics - Troubleshooting remote management issues - Remote management security and access control Exam Objectives: The objectives of the 050-694 certification exam are to assess the candidate's knowledge and skills in administering and managing Novell ZENworks 7 Desktop Management. The specific objectives include: - Understanding the architecture and components of ZENworks 7 - Configuring and managing user and device objects - Deploying software packages and updates - Implementing configuration policies and profiles - Managing applications and their associations - Performing imaging and personality migration tasks - Utilizing remote management capabilities - Troubleshooting common ZENworks 7 issues Exam Syllabus: The 050-694 exam syllabus outlines the specific syllabus and subtopics that will be covered in the exam. The syllabus may include: - ZENworks 7 architecture and components - User and device management in ZENworks 7 - Software distribution and update processes - Configuration policies and profiles - Application packaging and deployment - Imaging and personality migration techniques - Remote management capabilities and troubleshooting | ||||||||
| ZENworks 7 Desktop Management Administration Novell Administration study | ||||||||
Other Novell exams050-694 ZENworks 7 Desktop Management Administration050-696 Foundations of Novell Open Enterprise Server NetWare 050-701 Upgrading to Novell Open Enterprise Server for NetWare 050-708 SUSE Linux Enterprise Desktop 10 Administration 050-710 Novell Certified Linux Administrator 050-720 Novell Certified Linux Administrator 11 050-730 Certified Novell Identity Manager Administrator 050-886 Foundation of Novell Networking: NetWare 6.5 050-890 Advanced Novell Network Management;Netware 6.5 050-894 Novell ZENworks 7 Desktop Management Administrator 50-695 Novell eDirectory Design and Implementation:eDirectory 8.8 | ||||||||
| We have Tested and updated 050-694 exam braindumps with vce exam simulator for practice. With the use of their 050-694 exam braindumps material, you dont need to waste your chance on examining reference books and basically need to consume 10-20 hours to expert their 050-694 test questions and answers. This is just needed to get good marks in the 050-694 exam. | ||||||||
| Novell 050-694 ZENworks 7 Desktop Management Administration https://killexams.com/pass4sure/exam-detail/050-694 Question: 169 In preparation for migrating workstation personalities using ZENworks, you've created a Personality Store on your NetWare 6.5 server's VOL1 volume. Personalities will be stored in VOL1:\Ddna\Data. Your users reside within several different containers within the O=DA container, so you've granted O=DA Read, Create, Write, and File Scan rights to VOL1:\Ddna\Data. You've created an application object to collect workstation personalities when users login to the tree. However, when your users do this, the DNA engine won't run on user's workstations. Your users use Windows 2000 Professional systems with Internet Explorer 5.5 installed. What's causing the problem? A. The Personality Store must reside on the server's SYS volume. B. The Personality Store must reside at the root of a server volume. C. Personality Migration isn't compatible with Windows 2000 systems. D. Personality Migration doesn't support trees where users reside in dispersed contexts. E. Workstations need to have either Internet Explorer 6 or Microsoft XML Parser 3 installed. F. Users need the Erase right to the Personality Store in addition to the rights already granted. Answer: E Question: 170 84 When configuring a Workstation package, policies are available under 6 categories: General, Windows 9x, Windows NT-2000-XP, Windows NT, Windows 2000, and Windows XP. Which policies can be configured under the General policies category? (Choose 3.) A. Novell iPrint B. Windows Group C. Remote Control D. Workstation Imaging E. Computer Extensible F. Workstation Inventory Answer: A, C, D Question: 171 Which policy package can be used to configure the Database Location policy? (Choose 2.) A. User package B. Server package C. Container package D. Workstation package E. Service Location package Answer: B, E Question: 172 Which steps must you complete to configure a Standalone Workstation Inventory server?(Choose 2.) A. Configure the Roll-Up policy. B. Configure the Inventory Service object. C. Configure the Dictionary Update policy. D. Configure the Database Location policy. E. Configure the Workstation Inventory policy. Answer: D, E Question: 173 Click the Exhibit button to begin. Your user object is MHuffman.MKT.SLC. Which server package takes precedence when ZENworks determines effective policies? 85 A. SRVPKG_IS B. SRVPKG_SLC C. SRVPKG_MKT D. SRVPKG_CUST Answer: C Question: 174 Which configurations can be easily set using policies in the user package? (Choose 2.) A. Deploying applications across various LAN locations B. Tracking various types of hardware used in your organization C. Providing a full-access workstation environment for administrators D. Maintaining a workstation environment for users with special needs Answer: C, D Question: 175 Which tasks can the ZENworks Desktop Management Remote Management service accomplish? (Choose 3.) A. Remotely boot a powered-off managed workstation. B. Remotely blank out the managed workstation's screen. C. Remotely run executables on the managed workstation. D. Remotely modify the managed workstation's CMOS settings. E. Remotely access the SCSI ROM BIOS on workstations with SCSI adapters. 86 Answer: A, B, C Question: 176 Which files can you use to customize the functionality and appearance of the Application Browser view? (Choose 3.) A. Myapps.html B. NalApps.html C. Refresh.html D. Hf_style.css E. Nalview.html F. Nal_style.css G. App_style.css H. Appbrowser.html Answer: A, C, D Question: 177 Which DHCP option must be configured if ZENworks 6.5 Preboot Services and Dhcpsrvr.nlm are running on the same server? A. 53 B. 60 C. 100 D. 997 E. 001 Answer: B Question: 178 Which of the following describes the ZENworks Desktop Management application browser? A. A distributed application icon that is displayed in the system tray B. A web browser view that displays icons for distributed applications C. A standalone window that displays icons for distributed applications D. A distributed application icon that is displayed on the Windows desktop Answer: B Question: 179 87 Click the Point and Click button to begin. You are configuring an application object for a spreadsheet application, which is part of a suite of office productivity applications. You want all application objects in the suite to appear in the Start Menu. Click the option you would use to specify that Start Menu be automatically marked the next time you create an application object. Answer: 88 89 For More exams visit https://killexams.com/vendors-exam-list Kill your exam at First Attempt....Guaranteed! | ||||||||
|
A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer. The FDA will speed up its review of a novel antibody drug conjugate to treat certain patients with gynecologic cancer. The Food and Drug Administration (FDA) has granted a Fast Track designation to Rina-S (rinatabart sesutecan; PRO1184) for the treatment of patients with folate receptor alpha- (FRα) expressing high-grade serous or endometrioid platinum-resistant ovarian cancer, according to a press release from ProfoundBio, the manufacturer of the drug. The FDA grants Fast Track designations to drugs that fill an unmet need for a serious illness or condition. By granting one, the agency agrees to work with the company developing the therapy to speed up the review and potential approval. According to the agency’s website, “The purpose is to get important new drugs to the patient earlier.” "Our receipt of Fast Track designation from the FDA underscores their belief in the tremendous promise of Rina-S as a potential best-in-class FRα ADC to address the significant need for improved treatment options for advanced ovarian cancer," said Naomi Hunder, chief medical officer of ProfoundBio, in the press release. Rina-S is an antibody drug conjugate that targets FRα. Antibody drug conjugates — also known as ADCs — are a class of drug that works by targeting certain proteins found on cancer cells. Once the agent finds and attaches to the target, it releases the cancer-killing component of the medication. The targeted approach tends to lead to fewer side effects, because it tends to only attack tumor cells. MORE:Antibody Drug Conjugates ‘Make Chemotherapy Targeted’ for Patients With Cancer "FRα is a highly prevalent antigen in ovarian cancer and Rina-S has shown encouraging antitumor activity and tolerability in their phase 1 dose escalation study in ovarian and endometrial cancer patients across the full spectrum of FRα expression,” Hunder said. The safety and efficacy of Rina-S is being studied in the phase 1/2 PRO1184-001 clinical trial, which includes patients with locally advanced (spread to nearby tissue) and/or metastatic (spread to different parts of the body) solid tumors, including: epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer and mesothelioma. The study includes two parts, with the goal of Part A being to determine the best intravenous dosage of Rina-S. Results, which were reported in November 2023, showed that Rina-S has “encouraging antitumor activity and well-tolerated doses in heavily pretreated ovarian and endometrial cancer patients unselected for FRα expression,” according to the release. Now, Part B of the trial — which is currently enrolling patients in cancer treatment centers across the United States and China — will test the drug in a larger group of patients. The goal of Part B is to conduct a comprehensive analysis of the safety, tolerability and how the drug moves within the body (pharmacokinetics). Researchers plan on enrolling up to four different cohorts of patients, with up to 20 patients in each cohort. Patients will continue to receive Rina-S until they experience disease progression, unacceptable side effects, investigator decision, consent withdrawal, study termination, pregnancy or death, according to the trial’s listing on clinicaltrials.gov. Patients will not be eligible for enrollment on the trial if they’ve had another malignancy within the last three years; active central nervous system metastases (though patients with treated, stable central nervous system metastases may be permitted); uncontrolled severe infection; test positive for HBV, HCV or HIV; or used a strong P450 CYP3A inhibitor within the last two weeks. “We look forward to working closely with the FDA as they progress further clinical development and registrational studies for Rina-S,” Hunder concluded. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here. For Medicare beneficiaries with advanced prostate cancer (PCa), receipt of novel hormonal therapy (NHT) agents varies with race, according to a study published online Dec. 1 in JAMA Network Open. Ting Martin Ma, M.D., Ph.D., from the University of Washington in Seattle, and colleagues examined racial and ethnic disparities in use of NHT in a cohort study involving men diagnosed with de novo advanced PCa with Medicare Part A, B, and D coverage between Jan. 1, 2011, and Dec. 31, 2017. A total of 3,748 men were included in the study (8, 7, 78, and 7 percent were Black, Hispanic, White, and other race and ethnicity, respectively). The researchers found that 36 percent of the patients received one or more administration of NHT. The highest two-year NHT utilization rate was seen for White patients, followed by Hispanic patients, those with other race and ethnicity, and finally Black patients (27, 25, 23, and 20 percent, respectively). Compared with White patients, Black patients had significantly lower use of NHT, which persisted at five years (37 versus 44 percent) and beyond. The differences in NHT utilization were not significant for White versus Hispanic patients or those with other race or ethnicity. In patients with distant metastatic (M1) disease, trends of lower utilization among Black patients persisted (e.g., 51 versus 55 percent at five years). Black patients continued to have a significantly lower likelihood of NHT initiation after adjustment for patient, disease, and sociodemographic factors (adjusted subdistribution hazard ratio, 0.76). "Future studies are needed to uncover underlying causes and to systematically address these issues for more equitable care," the authors write. Several authors disclosed ties to the pharmaceutical and medical device industries. More information: Ting Martin Ma et al, Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer, JAMA Network Open (2023). DOI: 10.1001/jamanetworkopen.2023.45906 Copyright © 2023 HealthDay. All rights reserved. Citation: Receipt of novel hormonal therapy for advanced prostate cancer varies with race (2023, December 31) retrieved 5 January 2024 from https://medicalxpress.com/news/2023-12-receipt-hormonal-therapy-advanced-prostate.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. 
freep.com wants to ensure the best experience for all of their readers, so they built their site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on freep.com Just like a doctor adjusts the dose of a medication to the patient's needs, the expression of therapeutic genes, those modified in a person to treat or cure a disease via gene therapy, also needs to be maintained within a therapeutic window. Staying within the therapeutic window is important as too much of the protein could be toxic, and too little could result in a small or no therapeutic effect. Although the principle of therapeutic window has been known for a long time, there has been no strategy to implement it safely, limiting the potential applications of gene therapy in the clinic. In their current study published in the journal Nature Biotechnology, researchers at Baylor College of Medicine report on a technology to effectively regulate gene expression, a promising solution to fill this gap in gene therapy clinical applications. "Although there are several gene regulation systems used in mammalian cells, none has been approved by the U.S. Food and Drug Administration for clinical applications, mainly because those systems use a regulatory protein that is foreign to the human body, which triggers an immune response against it," said corresponding author Dr. Laising Yen, associate professor of pathology and immunology and of molecular and cellular biology at Baylor. "This means that the cells that are expressing the therapeutic protein would be attacked, eliminated or neutralized by the patient's immune system, making the therapy ineffective." For more than a decade, Yen and his colleagues have been working on this technology and now they have found a solution to overcome the main obstacles in its clinical use. "The solution they found does not involve a foreign regulatory protein that will evoke an immune response in patients. Instead, they use small molecules to interact with RNA, which typically do not trigger an immune response," Yen said. "Other groups also have made attempts to resolve this critical issue, but the drug concentrations they used are beyond what the FDA has approved for patients. They were able to engineer their system in such a way that it works at the FDA-approved dosage." A switch to turn genes on/off on cue Yen and his colleagues developed a system that turns genes on to different levels on cue using small molecules at FDA-approved doses. The switch is placed in the RNA, the copy of genetic material that is translated into a protein. This approach allows the researchers to control the protein's production a step back by controlling its RNA. The RNA of interest is first engineered to contain an extra polyA signal, akin to a "stop sign" that genes naturally use to mark the end of a gene. When the machinery of the cell detects a polyA signal in the RNA, it automatically makes a cut and defines the cut point as the end of the RNA. "In their system, they use the added polyA signal, not at the end, but at the beginning of the RNA, so the cut destroys the RNA and therefore the default is no protein production. It is turned off until they turn it on with the small molecule," Yen said. To turn on the gene at the desired level, the team engineered a switch on the RNA. They modified a section of the RNA near the polyA signal such that it can now bind to a small molecule, FDA-approved tetracycline in this case. "When tetracycline binds to that section that functions as a sensor on the RNA, it masks off the polyA signal, and the RNA will now be translated into protein," Yen said. Imagine the now possible future situation. A patient has received gene therapy that provides a gene to compensate for a malfunctioning gene that causes a medical condition. The gene the patient received has the switch, which allows the physician to control the production of the therapeutic protein. If the patient only requires a small amount of the therapeutic protein, then he/she will only take a small dose of tetracycline, which will turn on the therapeutic gene only a little. If the patient needs more therapeutic protein, then he/she would take more tetracycline to boost production. To stop production of the therapeutic protein, the patient stops taking tetracycline. In the absence of tetracycline, the switch will be back to its default off position. Some diseases may benefit from the presence of constant low levels of therapeutic protein. In that case, the technology has the flexibility to pre-adjust the default level to specified levels of protein expression while retaining the option of dialing up the expression with tetracycline. "This strategy allows us to be more precise in the control of gene expression of a therapeutic protein. It enables us to adjust its production according to disease's stages or tune to the patients' specific needs, all using the FDA-approved tetracycline dose," Yen said. "Our approach is not disease-specific, it can theoretically be used for regulating the expression of any protein, and potentially has many therapeutic applications. In addition, this system is more compact and easier to implement than the existing technologies. Therefore, it also can be very useful in the lab to turn a gene of interest on or off to study its function." Liming Luo, Jocelyn Duen-Ya Jea, Yan Wang and Pei-Wen Chao, all at Baylor College of Medicine, also contributed to this work. This work was supported by an E&M Foundation Pre-Doctoral Fellowship for Biomedical Research, NIH grants (R01EB013584, UM1HG006348, R01DK114356, R01HL130249, P30 CA125123 and S10 RR024574), Biogen SRA, seed fund from Department of Pathology and Immunology at Baylor College of Medicine and CPRIT Core Facility Support Award CPRIT-RP180672. In July, they reported that lecanemab (Leqembi) won full FDA approval to treat Alzheimer's disease. In this article, they look beyond anti-amyloid agents like lecanemab to see what other targets are being studied to prevent or treat Alzheimer's in 2024. 2023 was a landmark year for Alzheimer's disease, with lecanemab becoming the first treatment targeted at the disease process to receive full FDA approval. Reaching this milestone in Alzheimer's treatment was "a long journey," said Babak Tousi, MD, of the Cleveland Clinic in Ohio, an investigator in the lecanemab clinical trials. "We can affect the disease trajectory -- it's a small benefit, but it's still a benefit. They can slow it down." "This was a big step for us, and it's not just because of the effect of the disease treatment," Tousi pointed out. "We learned more about the disease and learned how to diagnose it more accurately, and how to look at the process of the disease progression and biomarkers." Another anti-amyloid drug, donanemab, may soon win FDA approval. But the Alzheimer's treatment landscape extends well beyond targeting amyloid-beta, with over 100 different drugs in phase I, II, or III clinical trials. "A pipeline of potential new treatments offers hope for the Alzheimer's and dementia community," Maria Carrillo, PhD, chief science officer of the Alzheimer's Association, said at the 2023 Alzheimer's Association International Conference (AAIC). "The progress and approvals we've seen, as well as the diversification of potential new therapies over the past few years, provides hope to those impacted by this devastating disease," Carrillo continued. "The anti-amyloid drugs newly approved by the U.S. Food and Drug Administration are an important first step in Alzheimer's treatment, but there is so much more to be done." Alternative Targets In 2023, the Alzheimer's drug development pipeline had 187 trials, the highest number on record, according to Jeffrey Cummings, MD, ScD, of the University of Nevada in Las Vegas, and co-authors in Alzheimer's & Dementia. Of 141 candidate treatments being studied, 79% were for disease-modifying therapies and were aimed not just at amyloid, but tau, inflammation, metabolic dysfunction, cell death, synaptic plasticity, and multiple other aspects of the disease. "Alternative targets for Alzheimer's disease treatment are being studied, such as tau pathology and biological mechanisms involved in aging," noted Julien Delrieu, MD, of Universite Paul Sabatier in Toulouse, France, and co-authors in a year-end review in Lancet Neurology. Age is the main risk factor for Alzheimer's and geroscience may offer therapeutic targets, Delrieu and co-authors observed. "Cellular senescence might contribute to Alzheimer's disease and is considered one of the most promising aging targets for the treatment of the disease," they wrote. A combination senolytic therapy of dasatinib (Sprycel) and the antioxidant quercetin was studied for the first time in patients with mild Alzheimer's disease in a proof-of-concept phase I trial, Delrieu and colleagues said. "This preliminary study showed a good safety profile and promising results on several Alzheimer's disease hallmarks (positive trend in inflammation and amyloid biomarkers) that need to be confirmed," they added. "Other geroscience-based therapies, such as intravenous mesenchymal stem cells, mTOR inhibitors, epigenetic therapies, sirtuins, or telomerase modulators, are also promising." New therapies aimed at tackling tau pathology also are making headway. "The clinical efficacy of tau-targeting therapies has yet to be established and some trials have failed; however, multiple trials are ongoing and new candidates continue to enter trials," wrote Einar Sigurdsson, PhD, of New York University Grossman School of Medicine in New York City, and co-authors in Nature Reviews: Neurology. Research suggests antisense oligonucleotides may reduce tau expression in humans, Sigurdsson and colleagues pointed out. Most new tau treatments in ongoing trials are immunotherapies, which can target tau intracellularly or extracellularly, they added. Repurposing Diabetes Drugs Ongoing Alzheimer's trials include repurposed diabetes drugs, noted Howard Fillit, MD, of the Alzheimer's Drug Discovery Foundation in New York City, and colleagues in the Journal of Prevention of Alzheimer's Disease. "Metformin and semaglutide [Ozempic], effective drugs against type 2 diabetes, are ideal candidates for repurposing to address the metabolic dysfunction in [Alzheimer's disease]," Fillit and co-authors wrote. Metformin is being studied for Alzheimer's dementia prevention in the phase II/III MAP trial. The diabetes drug is also being combined with healthy lifestyle changes in a novel trial called MET-FINGER, which aims to extend the success of the multidomain FINGER lifestyle study. In two phase III studies -- EVOKE and EVOKE Plus -- the effects of the glucagon-like peptide 1 receptor agonist semaglutide on the brain is being evaluated in early Alzheimer's disease. Another trial is assessing whether semaglutide can change tau accumulation in people with or without diabetes who are amyloid-positive and have no or mild cognitive impairment. CRISPR Gene Editing At the 2023 AAIC, researchers presented two early studies using CRISPR gene editing to potentially treat Alzheimer's disease. One study targeted the amyloid precursor protein (APP) gene that encodes amyloid-beta. The other used CRISPR technology to target the epigenome and reduce APOE4 expression in stem-cell-derived neurons and mouse models. "Studies such as these two that focus on the most advanced technologies -- in this case, CRISPR -- on moving Alzheimer's treatment and prevention forward are enthusiastically welcomed, and need to be multiplied many times over," Carrillo said at the conference. No single solution will likely solve Alzheimer's, she observed. "We envision a future where multiple treatments address every aspect of this most complex disease," Carrillo noted. "And that, once proven, the treatments can be combined in ways that complement and enhance each other to reduce risk, treat effectively, stop the progression, and eventually cure Alzheimer's disease and all other dementia." STOCKHOLM, Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has dosed the first patient with TNG348, a novel USP1 inhibitor. Tango received U.S. Food and Drug Administration clearance on its Investigational New Drug application for TNG348 in September 2023. TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers and 5% of pancreatic cancers. Tango is developing TNG348 from the preclinical USP1 program licensed from Medivir in 2020. In the study, TNG348 will be evaluated both as single agent and in combination with olaparib (PARP-inhibitor) in patients with BRCA1/2-mutant and other HRD+ cancers. Preclinical data has shown synergistic effect with PARP inhibitors in PARP naïve models, including models with resistance to PARP inhibitors. - "The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers. The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and they will continue to follow the clinical development of TNG348 with great anticipation," says Jens Lindberg, CEO of Medivir. Under the licensing agreement, Medivir is entitled to multiple development and commercial milestone payments as well as royalties on future sales. Dosing the first patient in a clinical trial triggers a milestone payment. For additional information, please contact; About Medivir Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com. The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/medivirs-licensee-tango-therapeutics-has-dosed-the-first-patient-with-tng348-a-novel-usp1-inhibitor-in-a-phase-12-clinical-study-302026095.html SOURCE Medivir
|
OBI Pharma, a clinical stage oncology company, announced that the US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a phase 1/2 study of its novel antibody – drug conjugate (ADC) cancer therapy targeting TROP2. OBI plans to enroll patients with advanced solid tumours, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and gastric cancer (GC), although several other cancers are also potential targets. OBI Pharma’s chief medical officer, Wayne Saville, M.D. noted, “The clinical trial intends to evaluate the safety, pharmacokinetics, and preliminary efficacy of OBI-992, a novel TROP2 ADC with best-in-class potential. They look forward to dosing the first patient in their phase 1/2 clinical study of OBI-992, which is expected to begin in early 2024.” Heidi Wang, Ph.D., OBI Pharma’s chief executive officer, added, “OBI-992 is a novel TROP2 ADC designed and engineered by OBI. It demonstrates outstanding preclinical efficacy, favourable safety, and high stability in numerous in-vivo studies compared to other TROP2 ADCs. They are excited to commence the first-in-human clinical trial of OBI-992. OBI Pharma strives to advance their promising therapeutics to the clinic for cancer patients.” OBI-992 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumour cells. TROP2 is highly expressed in a variety of solid tumours such as lung, breast, ovarian, and gastric cancer, rendering it an ideal target for cancer therapy. OBI-992 uses a unique hydrophilic, enzyme-cleavable linker that is stable in circulation but releases the cytotoxic payload inside tumour cells. OBI-992 demonstrates remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favourable safety profile in animal models. OBI Pharma, Inc., is a clinical stage oncology company that is headquartered in Taiwan and established in 2002. Its mission is to develop novel cancer therapeutic agents for patients with high unmet medical needs. | |||||||
050-694 approach | 050-694 techniques | 050-694 reality | 050-694 download | 050-694 helper | 050-694 exam contents | 050-694 history | 050-694 helper | 050-694 exam syllabus | 050-694 techniques | | ||||||||
Killexams exam Simulator Killexams Questions and Answers Killexams Exams List Search Exams |
Customer Reviews help to evaluate the exam performance in real test. Here all the reviews, reputation, success stories and ripoff reports provided.
We hereby announce with the collaboration of world's leader in Certification Exam Dumps and Real Exam Questions with Practice Tests that, we offer Real Exam Questions of thousands of Certification Exams Free PDF with up to date VCE exam simulator Software.
